Oliver McCammon, an analyst from LifeSci Capital, maintained the Buy rating on Perspective Therapeutics. The associated price target is $17.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Oliver McCammon has given his Buy rating due to a combination of factors surrounding Perspective Therapeutics’ ongoing clinical developments. The company is advancing three Pb-212-based radiopharmaceutical therapies, with a particular focus on the VMT-α-NET therapy designed for targeting SSTR2-expressing gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The upcoming update at ESMO in October is anticipated to provide significant insights into the efficacy and safety of this therapy, building on previous data that showed promising results in terms of objective response rate and manageable safety profile.
Additionally, the company’s strategic progress in its clinical trials, particularly the Phase 1/2a study of VMT-α-NET, is a key factor in the positive outlook. The anticipation of mature safety and preliminary efficacy data from the dose-finding cohorts further supports the potential competitive profile of VMT-α-NET in treating GEP-NETs. These developments, coupled with the company’s financial position, suggest a strong potential for growth and success, justifying the Buy rating.
In another report released today, Oppenheimer also maintained a Buy rating on the stock with a $14.00 price target.